<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978025</url>
  </required_header>
  <id_info>
    <org_study_id>colloidal silver and COVID-19</org_study_id>
    <nct_id>NCT04978025</nct_id>
  </id_info>
  <brief_title>Colloidal Silver, Treatment of COVID-19</brief_title>
  <official_title>The Value of Colloidal Silver in the Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Sahloul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Sahloul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Noble metals such as gold and silver have been appreciated for millennia not only for their&#xD;
      beauty but also for their ability to fight diseases.&#xD;
&#xD;
      Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique&#xD;
      physiochemical and chemical properties as well as biological features, such as&#xD;
      anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial&#xD;
      activities I&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Noble metals such as gold and silver have been appreciated for millennia not only for their&#xD;
      beauty but also for their ability to fight diseases.&#xD;
&#xD;
      Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique&#xD;
      physiochemical and chemical properties as well as biological features, such as&#xD;
      anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial&#xD;
      activities Infectious diseases account for more than 20% of global mortality and viruses are&#xD;
      responsible for about one-third of these deaths. Highly infectious viral diseases such as&#xD;
      severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus&#xD;
      disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious&#xD;
      threat to human health and the global economy.&#xD;
&#xD;
      The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2&#xD;
      (SARS-CoV-2) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chage of clinical status</measure>
    <time_frame>10 DAYS</time_frame>
    <description>the distribution of clinical status assessed on the 7-point ordinal scale on day 10 of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>ON 1 month</time_frame>
    <description>adverse events throughout the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of hospitalization</measure>
    <time_frame>ON 11 days</time_frame>
    <description>number of days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of the different respiratory assistance modes</measure>
    <time_frame>ON 11 days</time_frame>
    <description>the duration of the different respiratory assistance modes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>ON 1 month</time_frame>
    <description>the cause and the date of Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Silver Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)&#xD;
By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days&#xD;
By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal Silver</intervention_name>
    <description>Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)&#xD;
and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.</description>
    <arm_group_label>Silver Group</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies,&#xD;
             Sousse for symptoms of COVID -19 dating less than 10 days and having a positive&#xD;
             COVID-19 on the PCR test and typical scanner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pregnant or breastfeeding woman&#xD;
&#xD;
          -  patient with an expectation of survival of less than 24 hours&#xD;
&#xD;
          -  Dyspnea leading to heart failure&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Chronic respiratory failure&#xD;
&#xD;
          -  Renal failure, clearance &lt;20ml • min-1 • 1.73 • m-²&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boukef Riadh, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HU Sahloul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boukef Riadh, professor</last_name>
    <phone>00 216 98 676 745</phone>
    <email>riadboukef@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HU Sahloul, sousse, Tunisia</name>
      <address>
        <city>Sousse</city>
        <state>Itinéraire Ceinture Cité Sahloul</state>
        <zip>4054</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>boukef riadh, professor</last_name>
      <phone>73 369 411</phone>
      <email>riadboukef@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Universitaire Sahloul</investigator_affiliation>
    <investigator_full_name>Riadh Boukef</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>colloidal silver</keyword>
  <keyword>treatment</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

